Hepatitis Monthly

Published by: Kowsar

Immune Responses of Mice Immunized with HBsAg Formulated in Naloxone/Alum Mixture: Comparison to Fendrix Vaccine

Shima Nejati 1 , Sahar Mirzaee 2 , Hamid Reza Nouri 3 , Ramin Farhoudi 4 , Nabi Allah Namvar 4 , Mohammad Hossein Yazdi 5 , 6 , * and Mehdi Mahdavi 7 , *
Authors Information
1 Infectious Diseases and Tropical Medicine Research Center, Babol University of Medical Sciences, Babol, Iran
2 Department of Biotechnology, Faculty of Advanced Sciences and Technology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran (IAUPS)
3 Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
4 Laboratory Animal Science Department, Pasteur Institute of Iran, Karaj, Iran
5 Department of Pharmaceutical Biotechnology and Biotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
6 Evidence-Based Medicine Group, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
7 Department of Immunology, Pasteur Institute of Iran, Tehran, Iran
Corresponding Authors:
Article information
  • Hepatitis Monthly: March 01, 2017, 17 (3); e44536
  • Published Online: March 12, 2017
  • Article Type: Research Article
  • Received: December 5, 2016
  • Revised: February 2, 2017
  • Accepted: March 6, 2017
  • DOI: 10.5812/hepatmon.44536

To Cite: Nejati S, Mirzaee S, Nouri H R, Farhoudi R, Namvar N A, et al. Immune Responses of Mice Immunized with HBsAg Formulated in Naloxone/Alum Mixture: Comparison to Fendrix Vaccine, Hepat Mon. 2017 ; 17(3):e44536. doi: 10.5812/hepatmon.44536.

Abstract
Copyright © 2017, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Aiyer-Harini P, Ashok-Kumar HG, Kumar GP, Shivakumar N. An overview of immunologic adjuvants-A review. J Vaccines Vaccin. 2013; 4(1): 1-4[DOI]
  • 2. Budai J. [The role of vaccination in the prevention of communicable diseases]. Orv Hetil. 1998; 139(46): 2755-9[PubMed]
  • 3. Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. EMBO Mol Med. 2014; 6(6): 708-20[DOI][PubMed]
  • 4. Madalinski K, Kolakowska A, Godzik P. Current views on the persistence of immunity following hepatitis B vaccination. Przegl Epidemiol. 2015; 69(1): 47-51[PubMed]
  • 5. Puri P. Acute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis B. J Clin Exp Hepatol. 2013; 3(4): 301-12[DOI][PubMed]
  • 6. Orenbuch-Harroch E, Levy L, Ben-Chetrit E. Acute hepatitis B or exacerbation of chronic hepatitis B-that is the question. World J Gastroenterol. 2008; 14(46): 7133-7[PubMed]
  • 7. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology. 2000; 32(3): 635-9[DOI][PubMed]
  • 8. Nakayama T. [Influenza vaccine and adjuvant]. Yakugaku Zasshi. 2011; 131(12): 1723-31[PubMed]
  • 9. Levast B, Awate S, Babiuk L, Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S. Vaccine Potentiation by Combination Adjuvants. Vaccines (Basel). 2014; 2(2): 297-322[DOI][PubMed]
  • 10. Maisonneuve C, Bertholet S, Philpott DJ, De Gregorio E. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci U S A. 2014; 111(34): 12294-9[DOI][PubMed]
  • 11. Mohan T, Verma P, Rao DN. Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J Med Res. 2013; 138(5): 779-95[PubMed]
  • 12. Kashiwagi S, Brauns T, Gelfand J, Poznansky MC. Laser vaccine adjuvants. History, progress, and potential. Hum Vaccin Immunother. 2014; 10(7): 1892-907[DOI][PubMed]
  • 13. Petrovsky N, Cooper PD. Carbohydrate-based immune adjuvants. Expert Rev Vaccines. 2011; 10(4): 523-37[DOI][PubMed]
  • 14. Fathi M, Nezamzadeh R, Mahdavi M. Studying the effects of Naloxone-Alum adjuvant mixture on cytokines in model of multi-epitope vaccine in HIV-1. J Chem Health Risks. 2014; 4(2): 7-14
  • 15. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 2009; 30(1): 23-32[DOI][PubMed]
  • 16. Jamali A, Mahdavi M, Hassan ZM, Sabahi F, Farsani MJ, Bamdad T, et al. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. Int Immunol. 2009; 21(3): 217-25[DOI][PubMed]
  • 17. Aghasadeghi MR, Banifazl M, Aghakhani A, Eslamifar A, Vahabpour R, Ramezani A. No evidence for occult HBV infection in hepatitis B vaccine non-responders. Iran J Microbiol. 2014; 6(5): 350-3[PubMed]
  • 18. Tong NK, Beran J, Kee SA, Miguel JL, Sanchez C, Bayas JM, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005; 68(5): 2298-303[DOI][PubMed]
  • 19. Beran J, Hobzova L, Wertzova V, Kuriyakose S, Leyssen M, Surquin M, et al. Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum Vaccin. 2010; 6(7): 578-84[DOI][PubMed]
  • 20. Jazani NH, Parsania S, Sohrabpour M, Mazloomi E, Karimzad M, Shahabi S. Naloxone and alum synergistically augment adjuvant activities of each other in a mouse vaccine model of Salmonella typhimurium infection. Immunobiology. 2011; 216(6): 744-51[DOI][PubMed]
  • 21. Olofsen E, van Dorp E, Teppema L, Aarts L, Smith TW, Dahan A, et al. Naloxone reversal of morphine- and morphine-6-glucuronide-induced respiratory depression in healthy volunteers: a mechanism-based pharmacokinetic-pharmacodynamic modeling study. Anesthesiology. 2010; 112(6): 1417-27[DOI][PubMed]
  • 22. Jazani NH, Sohrabpour M, Mazloomi E, Shahabi S. A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine. FEMS Immunol Med Microbiol. 2011; 61(1): 54-62[DOI][PubMed]
  • 23. Jazani NH, Karimzad M, Mazloomi E, Sohrabpour M, Hassan ZM, Ghasemnejad H, et al. Evaluation of the adjuvant activity of naloxone, an opioid receptor antagonist, in combination with heat-killed Listeria monocytogenes vaccine. Microbes Infect. 2010; 12(5): 382-8[DOI][PubMed]
  • 24. Sacerdote P, di San Secondo VE, Sirchia G, Manfredi B, Panerai AE. Endogenous opioids modulate allograft rejection time in mice: possible relation with Th1/Th2 cytokines. Clin Exp Immunol. 1998; 113(3): 465-9[DOI][PubMed]
  • 25. Sacerdote P, Gaspani L, Panerai AE. The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in normal and skin-grafted mice. Ann N Y Acad Sci. 2000; 917: 755-63[PubMed]
  • 26. Motaharinia Y, Rezaee MA, Rashidi A, Jalili A, Rezaie MJ, Shapouri R, et al. Induction of protective immunity against brucellosis in mice by vaccination with a combination of naloxone, alum, and heat-killed Brucella melitensis 16 M. J Microbiol Immunol Infect. 2013; 46(4): 253-8[DOI][PubMed]
  • 27. Jamali A, Mahdavi M, Shahabi S, Hassan ZM, Sabahi F, Javan M, et al. Naloxone, an opioid receptor antagonist, enhances induction of protective immunity against HSV-1 infection in BALB/c mice. Microb Pathog. 2007; 43(5-6): 217-23[DOI][PubMed]
  • 28. Gherardi RK, Eidi H, Crepeaux G, Authier FJ, Cadusseau J. Biopersistence and brain translocation of aluminum adjuvants of vaccines. Front Neurol. 2015; 6: 4[DOI][PubMed]
  • 29. Dezfuli HT, Shahbazzadeh D, Eidi A, Bagheri KP, Pakravan N, Amini S, et al. Induction of IFN-gamma cytokine response against hepatitis B surface antigen using melittin. Gastroenterol Hepatol Bed Bench. 2014; 7(2): 108-17[PubMed]
  • 30. Di Pasquale A, Preiss S, Tavares Da Silva F, Garcon N. Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines (Basel). 2015; 3(2): 320-43[DOI][PubMed]
  • 31. Jahangiri S, Abtahi Froushani SM, Delirezh N. Combination immunotherapy with extract of heated 4T1 and naloxone in mouse model of breast cancer. Turk J Med Sci. 2016; 46(2): 518-23[DOI][PubMed]
  • 32. Mazloomi E, Jazani NH, Shahabi S. A novel adjuvant, mixture of alum and the beta-adrenergic receptor antagonist propranolol, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine. Vaccine. 2012; 30(16): 2640-6[DOI][PubMed]
  • 33. Jafarzadeh A, Shokri F. The antibody response to HBs antigen is regulated by coordinated Th1 and Th2 cytokine production in healthy neonates. Clin Exp Immunol. 2003; 131(3): 451-6[DOI][PubMed]
  • 34. Goncalves L, Albarran B, Salmen S, Borges L, Fields H, Montes H, et al. The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology. 2004; 326(1): 20-8[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments